Swissmedic expands the authorisation for Pandemrix
Bern, 19.11.2009 - Swissmedic, the Swiss Agency for Therapeutic Products, has expanded the authorisation for the A(H1N1) vaccine Pandemrix by GlaxoSmithKline. With immediate effect, the vaccine against this type of influenza is now authorised for those aged over 60. The basis for expanding the authorisation is clinical data proving the effectiveness of this vaccine for the said age group. Pandemrix is thus authorised for persons over the age of 18.
Swissmedic will continue to provide information on modifications to the existing authorisations for vaccines against the pandemic as soon as new data is available. In doing so, it will take international developments in this area into consideration.
Undesirable effects
Patients are urged to contact their doctor or pharmacists in the case of severe or unusual symptoms following vaccination. Swissmedic is providing health care professionals with a special online system to report suspected undesirable effects in order to constantly monitor the safety of the A(H1N1) vaccine.
For further information, such as details of current recommendations regarding vaccination issued by the Federal Commission for issues related to vaccines, please consult the website www.pandemia.ch by the Federal Office of Public Health (FoPH) or use the FoPH hotline on: 031 322 2100.
Address for enquiries
Joachim Gross, head of press office, Tel. 031 322 02 76
Publisher
Swiss Agency for Therapeutic Products
http://www.swissmedic.ch/?lang=2
